Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”
February 9, 2015

The BIO CConference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”

Pharmidex will be attending

The BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.


Those attending the conference will have the opportunity to explore a broad variety of industry related investment opportunities. Additionally delegates would have a chance to network with institutional investors, industry analysts & senior biotechnology executives. 


Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO One-on-One Partnering provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.


The event will be taking place on the 9-10 February 2015, New York City, NY, USA.

World Asthma Day 🌍

May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.

Funding Opportunity for Early-Stage Innovators in Scotland

May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN

We’re pleased to introduce the Pharmidex Senior Management Team

April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.
More Posts